Sage Journals: Discover world-class research

Abstract

Background

The role of extended thromboprophylaxis is established for surgical patients, but not yet for hospitalised medical patients.

Design

This systematic review and meta-analysis sought to explore the role of extended thromboprophylaxis for medically ill hospitalised patients.

Methods

Medline, EMBASE and Cochrane Libraries were searched and five randomised controlled trials were identified, comprising 20,046 extended and 20,078 standard duration thromboprophylaxis patients.

Results

Allocation to extended treatment, compared with standard duration therapy, significantly reduced the risk of symptomatic deep vein thrombosis (relative risk (RR) 0.47, 95% confidence interval (CI) 0.29–0.78, P = 0.003) and non-fatal pulmonary embolism (RR 0.59, 95% CI 0.39–0.91, P = 0.02). The risk of venous thromboembolism-related death was comparable between the extended and standard duration treatment groups (RR 0.81, 95% CI 0.6–1.09, P = 0.16). Extended treatment also doubled the risk of major bleeding (RR 2.04, 95% CI 1.42–2.91, P < 0.001), without significantly affecting the risk of intracranial bleeding or bleeding-associated death. The cost of preventing one symptomatic deep vein thrombosis and non-fatal pulmonary embolism was found to be £24,972 (€27,969) and £45,148 (€50,566), respectively, which outweigh the direct cost of managing established venous thromboembolism as previously reported.

Conclusions

Extended duration thromboprophylaxis caused a reduction in the risk of venous thromboembolic events, but also a numerically comparable increase in major bleeding. Further trials are required in high-risk subpopulations who may derive mortality benefits from treatment. Only then could a change in current policy and practice be supported.

Keywords

Thromboprophylaxis venous thromboembolism cost analysis

Get full access to this article

View all access options for this article.

References

Cohen

Agnelli

Anderson

et al. the VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe . The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756–764.

Grosse

Nelson

Nyarko

et al . The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res 2016; 137: 3–10.

Lassen

Gallus

Raskob

et al . for the ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487–2498.

Lassen

Ageno

Borris

et al . for the RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776–2786.

Falck-Ytter

Francis

Johanson

et al . Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e278S–e325S.

Eriksson

Borris

Friedman

et al . for the RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765–2775.

Bergqvist

Benoni

Bjorgell

et al . Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696–700.

Samama

Cohen

Darmon

et al . A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793–800.

Leizorovicz

Cohen

Turpie

et al . for the PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874–879.

10.

Fraisse

Holzapfel

Couland

et al . Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000; 161: 1109–1114.

11.

Amin

Varker

Princic

et al . Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med 2012; 7: 231–238.

12.

Cohen

Spiro

Buller

et al. for the MAGELLAN Investigators . Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368: 513–523.

13.

Cohen

Harrington

Goldhaber

et al . for the APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016; 375: 534–544.

14.

Hull

Schellong

Tapson

et al . EXCLAIM Study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010; 153: 8–18.

15.

Goldhaber

Leizorovicz

Kakkar

et al . for the ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365: 2167–2177.

16.

Spyropoulos

Ageno

Albers

et al . Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018; 379: 1118–1127.

17.

Kahn

Lim

Dunn

et al . Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e195S–e226S.

18.

Moher

Liberati

Tetzlaff

et al . and the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.

19.

Sterne JAC, Egger M, Moher D, et al. (eds). Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (eds) Cochrane Handbook for Systematic Reviews of Interventions, version 5.2.0 (updated June 2017). Cochrane, 2017. www.training.cochrane.org/handbook (accessed 23 February 2019).

20.

Cohen

Spiro

Spyropoulos

et al . for the MAGELLAN Study Group. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost 2014; 12: 479–487.

21.

Spyropoulos

Anderson

Jr FitzGerald

et al . for the IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140: 706–714.

22.

Mahan

Liu

Turpie

et al . External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE–VALOURR). Thromb Haemost 2014; 112: 692–699.

23.

Rosenberg

Eichorn

Alarcon

et al . External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc 2014; 3: e001152.

24.

Glisic

Shahzad

Tsoli

et al . Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol 2018; 25: 1042–1052.

25.

Tilleul

LaFuma

Colin

et al . Estimated annual costs of prophylaxis and treatment of venous thromboembolic events associated with major orthopedic surgery in France. Clin Appl Thromb/Hemost 2006; 12: 473–484.

26.

Ruppert

Steinle

Lees

. Economic burden of venous thromboembolism: a systematic review. J Med Econ 2011; 14: 65–74.

27.

Bergqvist

Jendteg

Johansen

et al . Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med 1997; 126: 454–457.

28.

Jakobsen

Kolodziejczyk

Klausen Fredslund

et al . Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation – a nationwide cohort study. BMC Health Serv Res 2017; 17: 398.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.41 MB

The case for extended thromboprophylaxis in medically hospitalised patients – not yet made

Abstract

Background

Design

Methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material